Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Check-Cap Ltd. (CHEK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2500+1.0500 (+32.81%)
At close: 04:00PM EST
4.2000 -0.05 (-1.18%)
After hours: 07:44PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close3.2000
Open3.2600
Bid4.2000 x 2200
Ask4.5000 x 1800
Day's Range3.1900 - 4.2500
52 Week Range1.8800 - 14.0000
Volume210,560
Avg. Volume60,441
Market Cap24.65M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.2130
Earnings DateApr 05, 2023 - Apr 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CHEK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Check-Cap Ltd.
    Analyst Report: Quest Diagnostics IncorporatedQuest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • PR Newswire

    Check-Cap Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2022.

  • PR Newswire

    Check-Cap Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the second quarter and six months ended June 30, 2022.

  • PR Newswire

    Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), announces that on June 22, 2022, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is eligible for an additional 180 calendar day period, or until Dec

Advertisement
Advertisement